@article{c7f3043a-18b5-432c-9908-4f25f7d40071,
author = {Tomasz Bochenek},
title = {Innowacja lekowa w świetle ustawy refundacyjnej},
journal = {Zdrowie Publiczne i Zarządzanie},
volume = {2010},
number = {Tom 8, Numer 2},
year = {2010},
issn = {1731-7398},
pages = {87-95},keywords = {innowacja lekowa; ceny leków; refundacja leków; polityka lekowa; zwrot przychodów; podział ryzyka},
abstract = {The Pharmaceutical Innovation and the Reimbursed Act 

	The innovation in pharmaceutical sector can be characterized as incremental. The expectations towards new drugs are very high but the access of Polish patients to the pharmaceutical innovation is limited. Role and perception of this innovation within the Polish health care policy are not signaled coherently and unambiguously. The Reimbursement Act is an important new legal act, which was intensely debated in the second half of 2010 and the first half of 2011.This legal act changes conditions of functioning of virtually all subjects acting on the market of pharmaceuticals which are financed from public sources. The Reimbursement Act introduces thorough changes into the pharmaceutical policy and pricing and reimbursement policies. These changes can influence the pharmaceutical innovation in the Polish health care system. It is impossible to circumscribe the direction of these changes decisively. However, there is a hope for a summary positive influence of new regulations, so monitoring of a manner of implementation of the Reimbursement Act will be necessary.},
doi = {},
url = {https://ejournals.eu/czasopismo/zdrowie-publiczne-i-zarzadzanie/artykul/innowacja-lekowa-w-swietle-ustawy-refundacyjnej}
}